Cardiovascular adverse events associated with PARP inhibitors for ovarian cancer: a real world study (RWS) with Bayesian disproportional analysis based on the FDA adverse event reporting system (FAERS)-Reference-Cited by-同舟云学术

Cardiovascular adverse events associated with PARP inhibitors for ovarian cancer: a real world study (RWS) with Bayesian disproportional analysis based on the FDA adverse event reporting system (FAERS)

Published:2024-08-12 Issue: Volume: Page:1-8
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Yang Chenguang¹,Song Xuan²,Sun Hongmei¹,Chen Xi³,Liu Chengjiang⁴,Chen Min¹

Affiliation:

1. Department of Gynaecology and Obstetrics, Affiliated Xuancheng Hospital of Wannan Medical College, Xuancheng, Anhui Province, China

2. Department of General Medicine, Affiliated Xuancheng Hospital of Wannan Medical College, Xuancheng, Anhui Province, China

3. Department of Epidemiology and Statistics, School of Public Health, Medical College, Zhejiang University, Zhejiang, China

4. Department of General Medicine, Affiliated Anqing First People’s Hospital of Anhui Medical University, Hefei, China

Funder

Affiliated Xuancheng Hospital of Wannan Medical College

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2024.2390640

Reference43 articles.

1. American cancer society: key statistics for ovarian cancer. 2023. Available from: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html

2. A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: Diagnostic and therapeutic perspectives

3. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry

4. Ovarian cancer statistics, 2018

5. Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4